Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Holding MLYS?
Track your performance easily
MLYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.85 - $16.91
Previous Close$11.98
Volume72.50K
Average Volume (3M)229.29K
Market Cap
$595.73M
Enterprise Value$527.87M
Total Cash (Recent Filing)$67.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Nov 05, 2024EPS Estimate
-$0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.69
Shares Outstanding49,726,675
10 Day Avg. Volume101,353
30 Day Avg. Volume229,288
Standard Deviation0.19
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.20
Forecast
1Y Price Target
$34.25Price Target Upside192.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Mineralys Therapeutics, Inc. News
PremiumCompany Announcements
Mineralys Therapeutics Welcomes Dr. Gold to Board of Directors
Bulls Say, Bears Say
Bulls Say
Clinical TrialsADVANCE-HTN represents one of the most rigorous studies in hypertension to date.
Drug DevelopmentLorundrostat shows potential to unlock value with a $10-$15 per share upside if upcoming trial results are favorable.
Financial PerformanceAfter a private financing in February added $116M to the balance sheet, management expects current cash of $339M to fund clinical programs into 2026.
Bears Say
Financial PerformanceOperational expenses are increasing due to the cost of ongoing studies, impacting the company's short-term financials.
Future ProjectionsOperational expenses are expected to increase due to the cost of rollover of hypertension and chronic kidney disease patients to ongoing studies, impacting the company's short-term financials.
Operational Expenses1Q OpEx increased 28% quarter-over-quarter driven by increased clinical trial costs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $5.85 and its highest was $16.91 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Aug 13, 2024. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$0.13.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -$0.86.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 49,726,673 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went down -22.823%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Among the largest hedge funds holding Mineralys Therapeutics, Inc.’s share is RA Capital Management. It holds Mineralys Therapeutics, Inc.’s shares valued at 57M.
---
Mineralys Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (192.99% Upside)
$34.25 (192.99% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 77.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.08%
12-Months-Change
Fundamentals
Return on Equity
-41.62%
Trailing 12-Months
Asset Growth
9.37%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
---
MLYS Earnings Call
Q2 2024
0:00 / 0:00
---
MLYS Stock 12 Month Forecast
Average Price Target
$34.25
▲(192.99% Upside)
Technical Analysis
Axsome Therapeutics
―
SAGE Therapeutics
―
Blueprint Medicines
―
Intra-Cellular Therapies
―
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-6.37%
assigned a buy rating 14 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -6.37% per trade.
---